random sequence generation (AstraZeneca ltd)
90
Structured Review
AstraZeneca ltd
random sequence generation
Random Sequence Generation, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random+sequence/random+sequence+generation/pmc11663505-183-0-27
Average 90 stars, based on 1 article reviews
Random Sequence Generation, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random+sequence/random+sequence+generation/pmc11663505-183-0-27
Average 90 stars, based on 1 article reviews
random sequence generation - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer Article Snippet: Random assignment was co-ordinated in the UK by the Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham; in Sweden, Denmark, Finland and Norway by the Randomisation Bureau, Danish Cancer Society, Aarhus, Denmark; and for all other centres by the local AstraZeneca Pharma Office Allocation concealment (selection bias) High risk Participant numbers were allocated sequen- tially by entry as participants entered the trial Blinding of participants and personnel (performance bias) overall survival, cancer-specific mortality, biochemical progression Unclear risk No blinding for overall survival and cancerspecific mortality. Sequencing:Article Title: Long‐acting beta 2 ‐agonists for chronic obstructive pulmonary disease Article Snippet: .. Article Title: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease Article Snippet: .. Article Title: Fulvestrant for hormone-sensitive metastatic breast cancer Article Snippet: Published by John Wiley & Sons, Ltd. FIRST (Continued) Current or prior malignancy (except breast cancer or adequately treated skin cancer or in situ carcinoma of the cervix) Abnormal laboratory tests History of bleeding diatheses Long-term anticoagulant therapy Hypersensitivity to excipients of fulvestrant, AIs, or castor oil Any severe concomitant conditions Some authors were in receipt of research funding from AstraZeneca. .. Unspecified whether AstraZeneca was involved in the analyses Risk of bias Bias Authors’ judgement Support for Selection:Article Title: Long‐acting beta 2 ‐agonists for chronic obstructive pulmonary disease Article Snippet: .. Article Title: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease Article Snippet: .. Article Title: Fulvestrant for hormone-sensitive metastatic breast cancer Article Snippet: Published by John Wiley & Sons, Ltd. FIRST (Continued) Current or prior malignancy (except breast cancer or adequately treated skin cancer or in situ carcinoma of the cervix) Abnormal laboratory tests History of bleeding diatheses Long-term anticoagulant therapy Hypersensitivity to excipients of fulvestrant, AIs, or castor oil Any severe concomitant conditions Some authors were in receipt of research funding from AstraZeneca. .. Unspecified whether AstraZeneca was involved in the analyses Risk of bias Bias Authors’ judgement Support for |